VIGL News

News
all
press releases
Sanofi Q2 Earnings & Sales Miss, 2025 Top-Line View Raised, Stock Down
SNY misses Q2 earnings and sales estimates but lifts 2025 sales outlook on strong Dupixent and vaccine momentum.
Zacks
Sanofi Q2 Earnings & Sales Miss, 2025 Top-Line View Raised, Stock Down
SNY misses Q2 earnings and sales estimates but lifts 2025 sales outlook on strong Dupixent and vaccine momentum.
Zacks
More News
The mean of analysts' price targets for Vigil Neuroscience (VIGL) points to a 26.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks
Under the terms of the deal, Sanofi will acquire all outstanding common shares of Vigil for $8 per share in cash at closing.
Stocktwits

Advertisement|Remove ads.